Ultragenyx To Present At Upcoming Investor Conferences

NOVATO, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences:
  • Shalini Sharp, the company's Chief Financial Officer, will present at the Credit Suisse 25th Annual Healthcare Conference on Tuesday, November 8, 2016 at 2:30pm MT in Scottsdale, AZ.
  • Tom Kassberg, the company's Chief Business Officer, will present at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at 1:30pm ET in New York, NY.

The live and archived webcasts of the company presentations will be accessible from the company's website at http://ir.ultragenyx.com/events.cfm. The replays will be available for 90 days.

About Ultragenyx

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.Investors & MediaRyan Martins844-758-7273

Primary Logo

If you liked this article you might like

Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers

Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct